Justin Gover
Independent Director
Justin Gover is a seasoned biotech leader with more than 25 years of experience in the UK and US, including as founding CEO of GW Pharmaceuticals. Under his leadership from 1999 to 2021, GW became a global leader in cannabinoid science, successfully developing and commercializing Epidiolex—the first FDA-approved plant-derived cannabinoid medicine—for childhood-onset epilepsy.
During his tenure, Justin led GW through multiple equity financings, public listings in London and on Nasdaq, and ultimately its $7.2 billion acquisition by Jazz Pharmaceuticals. He built a fully integrated pharmaceutical company with global R&D, manufacturing, and commercial operations.
Justin currently serves on the boards of several public and private companies as well as non-profit organizations focused on epilepsy and children’s health. He holds an MBA from the INSEAD business school in France and a BSc (Hons) from Bristol University, UK.